Archive
2023 96 97 98 99 100 101
2022 90 91 92 93 94 95
2021 84 85 86 87 88 89
2020 78 79 80 81 82 83
2019 72 73 74 75 76 77
2018 66 67 68 69 70 71
2017 60 61 62 63 64 65
2016 54 55 56 57 58 59
2015 48 49 50 51 52 53
2014 42 43 44 45 46 47
News
Submit your article
Newsletter


Issue № 84. February 2021

Economic Effect of Biosimilars Government Procurement on the Monoclonal Antibody Market in Russia

Danila A. Uvarov

Postgraduate student, Faculty of Economics, Department of Economics of Innovation, Lomonosov Moscow State University, Moscow, Russian Federation.
E-mail: bluesvera@gmail.com
ORCID ID: 0000-0002-9954-3931

Biopharmaceutical market, particularly monoclonal antibodies segment has been going through serious changes for the last ten years. Along with emergence of innovative drugs, new indications for existing medications and new ways of drug delivery, biosimilars, appear, whose main idea is not only to bring profit to pharmaceutical companies but also increase availability of modern ways of life-threatening diseases treatment. Key competitive advantage of biosimilars is usually a discounted price in comparison with an originator drug. This article tries to evaluate the economic effect of approved monoclonal antibody biosimilars procurement in 2018 and 2019. According to the study results weighted average prices for two out of seven biosimilars appeared to be significantly lower than prices for original drugs (Avegra — 78,53% and Elizaria — 76,6% from originator price); four biosimilars (Infliximab Biocad — 94,12%, Flammegis — 98,42. Acellbia — 98,85, Redditux — 97,33% from riginators price) did not demonstrate significant discounts; one biosimilar (Herticad — 115,31% from weighted average price of original drug) turned out to be more expensive than its competitor Herceptin. The economic effect in terms of the amount of savings due to biosimilar procurement was calculated based on the analysis of weighted average prices. Thus, the greatest contribution to the budget savings was made by the Elizaria, which made it possible to use approximately 3.3 billion rubles more effectively during 2018 and 2019. In addition to Elizaria, a significant contribution was made by the procurement of Avegra, which saved 2.9 billion rubles. The procurement of four other biosimilars saved about 246 million rubles, while the purchase of Herticad required an additional 1.4 billion rubles.

Keywords

Biopharmaceutical market, biosimilars, eculizumab, bevacizumab, trastuzumab, government procurement, budget savings, monoclonal antibody.

DOI: 10.24412/2070-1381-2021-84-129-146

Comments:
No material published in this journal may be reproduced in print or in electronic form without a link to "E-journal. Public Administrarion".
119991, Room A-710, Shuvalovskiy building, Lomonosov Moscow State University
(27/4, Lomonosovskiy Avenue); phone: +7 (495) 930-85-71
Copyright © 2015 SPA MSU


Яндекс.Метрика